JP2020500164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500164A5 JP2020500164A5 JP2019521093A JP2019521093A JP2020500164A5 JP 2020500164 A5 JP2020500164 A5 JP 2020500164A5 JP 2019521093 A JP2019521093 A JP 2019521093A JP 2019521093 A JP2019521093 A JP 2019521093A JP 2020500164 A5 JP2020500164 A5 JP 2020500164A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- telllipresin
- administered
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 239000002775 capsule Substances 0.000 claims description 22
- 206010003445 Ascites Diseases 0.000 claims description 17
- 239000006186 oral dosage form Substances 0.000 claims description 17
- 208000007232 portal hypertension Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000001953 Hypotension Diseases 0.000 claims description 6
- 230000036543 hypotension Effects 0.000 claims description 6
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 claims description 5
- 206010056091 Varices oesophageal Diseases 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 229940097320 beta blocking agent Drugs 0.000 claims description 5
- 208000024170 esophageal varices Diseases 0.000 claims description 5
- 201000010120 esophageal varix Diseases 0.000 claims description 5
- 230000002008 hemorrhagic effect Effects 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000011200 hepatorenal syndrome Diseases 0.000 claims description 4
- 208000028893 postprandial hypotension Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 3
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010021036 Hyponatraemia Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 230000003907 kidney function Effects 0.000 claims description 2
- 230000036514 plasma sodium concentration Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 108010010056 Terlipressin Proteins 0.000 claims 6
- 229960003813 terlipressin Drugs 0.000 claims 6
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 4
- 229960001094 midodrine Drugs 0.000 description 4
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 3
- 229960002011 fludrocortisone Drugs 0.000 description 3
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960001104 droxidopa Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023108121A JP2023120445A (ja) | 2016-10-21 | 2023-06-30 | テルリプレシン組成物およびその使用方法 |
| JP2024194379A JP2025020319A (ja) | 2016-10-21 | 2024-11-06 | テルリプレシン組成物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410971P | 2016-10-21 | 2016-10-21 | |
| US62/410,971 | 2016-10-21 | ||
| US201762472291P | 2017-03-16 | 2017-03-16 | |
| US62/472,291 | 2017-03-16 | ||
| PCT/US2017/057601 WO2018075897A1 (en) | 2016-10-21 | 2017-10-20 | Terlipressin compositions and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108121A Division JP2023120445A (ja) | 2016-10-21 | 2023-06-30 | テルリプレシン組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500164A JP2020500164A (ja) | 2020-01-09 |
| JP2020500164A5 true JP2020500164A5 (enExample) | 2020-11-26 |
Family
ID=62019439
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521093A Withdrawn JP2020500164A (ja) | 2016-10-21 | 2017-10-20 | テルリプレシン組成物およびその使用方法 |
| JP2023108121A Withdrawn JP2023120445A (ja) | 2016-10-21 | 2023-06-30 | テルリプレシン組成物およびその使用方法 |
| JP2024194379A Pending JP2025020319A (ja) | 2016-10-21 | 2024-11-06 | テルリプレシン組成物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108121A Withdrawn JP2023120445A (ja) | 2016-10-21 | 2023-06-30 | テルリプレシン組成物およびその使用方法 |
| JP2024194379A Pending JP2025020319A (ja) | 2016-10-21 | 2024-11-06 | テルリプレシン組成物およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10993984B2 (enExample) |
| EP (2) | EP3528828B1 (enExample) |
| JP (3) | JP2020500164A (enExample) |
| AU (2) | AU2017345720B2 (enExample) |
| CA (1) | CA3037581A1 (enExample) |
| ES (1) | ES3023754T3 (enExample) |
| IL (2) | IL265761B2 (enExample) |
| MA (1) | MA46586A (enExample) |
| WO (1) | WO2018075897A1 (enExample) |
| ZA (1) | ZA201901912B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| AU2016215350B2 (en) | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
| CN109223720B (zh) * | 2018-09-12 | 2020-11-27 | 南京康舟医药科技有限公司 | 注射用醋酸特利加压素冻干粉针剂的制备方法 |
| WO2021127234A2 (en) * | 2019-12-20 | 2021-06-24 | Northwestern University | Terlipressin-octadecanedioic acid conjugate for vasoconstrictive therapy |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN114306250B (zh) * | 2021-11-26 | 2023-07-14 | 苏州天马医药集团天吉生物制药有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH455823A (de) | 1964-08-01 | 1968-05-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von Peptiden |
| EP1188443A1 (en) * | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
| RU2415149C2 (ru) | 2006-02-10 | 2011-03-27 | Ферринг Б.В. | Пептидные соединения |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| AU2015201581B2 (en) | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| US20110311621A1 (en) * | 2010-03-16 | 2011-12-22 | Paul Salama | Pharmaceutical compositions and methods of delvery |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| JO3371B1 (ar) | 2013-07-26 | 2019-03-13 | Ferring Bv | ناهضات مستقبل فاسوبريسين 2 |
| JP6673915B2 (ja) | 2014-10-24 | 2020-03-25 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | １型肝腎症候群患者の治療方法 |
| KR102345773B1 (ko) | 2015-03-30 | 2021-12-31 | 서니브룩 리서치 인스티튜트 | 암 치료 방법 |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2017
- 2017-10-20 EP EP17862085.2A patent/EP3528828B1/en active Active
- 2017-10-20 CA CA3037581A patent/CA3037581A1/en active Pending
- 2017-10-20 AU AU2017345720A patent/AU2017345720B2/en active Active
- 2017-10-20 MA MA046586A patent/MA46586A/fr unknown
- 2017-10-20 IL IL265761A patent/IL265761B2/en unknown
- 2017-10-20 JP JP2019521093A patent/JP2020500164A/ja not_active Withdrawn
- 2017-10-20 ES ES17862085T patent/ES3023754T3/es active Active
- 2017-10-20 EP EP25152377.5A patent/EP4516803A3/en active Pending
- 2017-10-20 IL IL313083A patent/IL313083A/en unknown
- 2017-10-20 US US16/343,232 patent/US10993984B2/en active Active
- 2017-10-20 WO PCT/US2017/057601 patent/WO2018075897A1/en not_active Ceased
-
2019
- 2019-03-27 ZA ZA2019/01912A patent/ZA201901912B/en unknown
-
2021
- 2021-11-11 US US17/524,022 patent/US20220313773A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108121A patent/JP2023120445A/ja not_active Withdrawn
- 2023-10-27 AU AU2023255036A patent/AU2023255036A1/en active Pending
-
2024
- 2024-01-31 US US18/429,227 patent/US20250000933A1/en active Pending
- 2024-11-06 JP JP2024194379A patent/JP2025020319A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500164A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2019131596A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| US20220000824A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| JP2018527392A5 (enExample) | ||
| JP2007515469A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| Richardson et al. | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | |
| JP2018514510A5 (enExample) | ||
| JP2012526852A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| Kaplan et al. | Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co‐administered enteric‐coated mycophenolate sodium | |
| JP2016511259A5 (enExample) | ||
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| JP2019501226A5 (enExample) | ||
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| JP2023109947A5 (enExample) | ||
| JP2009504774A5 (enExample) | ||
| Jang et al. | Drug dosing considerations in continuous renal replacement therapy | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| Li et al. | Comparison of efficacy and safety between tacrolimus and cyclosporine combined with corticosteroids in patients with idiopathic membranous nephropathy: a randomized controlled trial | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| JP2020510073A5 (enExample) |